LSL Pharma Group Inc.
LSL.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 30.88% | -4.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 30.88% | -4.03% | |||
| Cost of Revenue | 35.44% | 6.37% | |||
| Gross Profit | 20.13% | -22.01% | |||
| SG&A Expenses | 23.31% | -35.73% | |||
| Depreciation & Amortization | -383.66% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.38% | -9.17% | |||
| Operating Income | 144.53% | 160.79% | |||
| Income Before Tax | 1,248.30% | 24.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1,235.69% | 24.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,235.69% | 24.95% | |||
| EBIT | 144.53% | 160.79% | |||
| EBITDA | 6.51% | 116.36% | |||
| EPS Basic | 1,208.00% | 30.56% | |||
| Normalized Basic EPS | 18.75% | 33.33% | |||
| EPS Diluted | 1,132.00% | 30.56% | |||
| Normalized Diluted EPS | 18.75% | 33.33% | |||
| Average Basic Shares Outstanding | 0.74% | 8.80% | |||
| Average Diluted Shares Outstanding | 0.57% | 8.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||